{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36017236", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "08", "Day": "16"}], "Language": ["eng"], "ELocationID": ["6044640", "10.1155/2022/6044640"], "Journal": {"ISSN": "1942-0994", "JournalIssue": {"Volume": "2022", "PubDate": {"Year": "2022"}}, "Title": "Oxidative medicine and cellular longevity", "ISOAbbreviation": "Oxid Med Cell Longev"}, "ArticleTitle": "Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products.", "Pagination": {"StartPage": "6044640", "MedlinePgn": "6044640"}, "Abstract": {"AbstractText": ["Among various cancers, breast cancer is the most prevalent type in women throughout the world. Breast cancer treatment is challenging due to complex nature of the etiology of disease. Cell division cycle alterations are often encountered in a variety of cancer types including breast cancer. Common treatments include chemotherapy, surgery, radiotherapy, and hormonal therapy; however, adverse effects and multidrug resistance lead to complications and noncompliance. Accordingly, there is an increasing demand for natural products from medicinal plants and foods. This review summarizes molecular mechanisms of signaling pathways in breast cancer and identifies mechanisms by which natural compounds may exert their efficacy in the treatment of breast cancer."], "CopyrightInformation": "Copyright \u00a9 2022 Esra K\u00fcpeli Akkol et al."}, "AuthorList": [{"Identifier": ["0000-0002-5829-7869"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Etiler, 06330 Ankara, Turkey."}], "LastName": "K\u00fcpeli Akkol", "ForeName": "Esra", "Initials": "E"}, {"Identifier": ["0000-0003-4223-2910"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Ayd\u0131nlar University, 34752 Istanbul, Turkey."}], "LastName": "Bardakci", "ForeName": "Hilal", "Initials": "H"}, {"Identifier": ["0000-0002-7434-3175"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Ayd\u0131nlar University, 34752 Istanbul, Turkey."}], "LastName": "Barak", "ForeName": "Timur Hakan", "Initials": "TH"}, {"Identifier": ["0000-0002-2619-1656"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10463, USA."}], "LastName": "Aschner", "ForeName": "Michael", "Initials": "M"}, {"Identifier": ["0000-0001-5829-6914"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey."}], "LastName": "\u015eeker Karatoprak", "ForeName": "G\u00f6k\u00e7e", "Initials": "G"}, {"Identifier": ["0000-0002-1736-4404"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, Abdul Wali Khan University Mardan, 23200 Mardan, Pakistan."}], "LastName": "Khan", "ForeName": "Haroon", "Initials": "H"}, {"Identifier": ["0000-0003-1054-6720"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China."}], "LastName": "Hussain", "ForeName": "Yaseen", "Initials": "Y"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Oxid Med Cell Longev", "NlmUniqueID": "101479826", "ISSNLinking": "1942-0994"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}], "MeshHeadingList": [{"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": ["drug therapy", "metabolism", "prevention & control"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}], "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Coughlin S. S., Ekwueme D. U. Breast cancer as a global health concern. Cancer Epidemiology . 2009;33(5):315\u2013318.", "ArticleIdList": ["19896917"]}, {"Citation": "Ferlay J., H\u00e9ry C., Autier P., Sankaranarayanan R. Breast Cancer Epidemiology . New York, NY: Springer; 2010. Global burden of breast cancer; pp. 1\u201319.", "ArticleIdList": ["10.1007/978-1-4419-0685-4_1"]}, {"Citation": "Helmrich S. P., Shapiro S., Rosenberg L., et al. Risk factors for breast cancer. American Journal of Epidemiology . 1983;117(1):35\u201345. doi: 10.1093/oxfordjournals.aje.a113513.", "ArticleIdList": ["10.1093/oxfordjournals.aje.a113513", "6823951"]}, {"Citation": "K\u00fcpeli Akkol E., G\u00fcra\u011fa\u00e7 Dereli F. T., Sobarzo-S\u00e1nchez E., Khan H. Roles of medicinal plants and constituents in gynecological cancer therapy: current literature and future directions. Current Topics in Medicinal Chemistry . 2020;20(20):1772\u20131790. doi: 10.2174/1568026620666200416084440.", "ArticleIdList": ["10.2174/1568026620666200416084440", "32297581"]}, {"Citation": "Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer . 2001;1:222\u2013231. doi: 10.1038/35106065.", "ArticleIdList": ["10.1038/35106065", "11902577"]}, {"Citation": "Li Y., Li S., Meng X., Gan R. Y., Zhang J. J., Li H. B. Dietary natural products for prevention and treatment of breast cancer. Nutrients . 2017;9(7):p. 728.", "ArticleIdList": ["PMC5537842", "28698459"]}, {"Citation": "Coates A., Abraham S., Kaye S. B., et al. On the receiving end patient perception of the side effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology . 1983;19(2):203\u2013208.", "ArticleIdList": ["6681766"]}, {"Citation": "Ahmed S., Khan H., Aschner M., Mirzae H., K\u00fcpeli Akkol E., Capasso R. Anticancer potential of furanocoumarins: mechanistic and therapeutic aspects. International Journal of Molecular Sciences . 2020;21:p. 5622.", "ArticleIdList": ["PMC7460698", "32781533"]}, {"Citation": "Doyle L. A., Yang W., Abruzzo L. W., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences . 1998;95(26):15665\u201315670. doi: 10.1073/pnas.95.26.15665.", "ArticleIdList": ["10.1073/pnas.95.26.15665", "PMC28101", "9861027"]}, {"Citation": "Ullah M. F. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pacific Journal of Cancer Prevention . 2008;9(1):1\u20136.", "ArticleIdList": ["18439063"]}, {"Citation": "Burstein H. J., Gelber S., Guadagnoli E., Weeks J. C. Use of alternative medicine by women with early stage breast cancer. New England Journal of Medicine . 1999;340(22):1733\u20131739.", "ArticleIdList": ["10352166"]}, {"Citation": "Adler S. R., Fosket J. R. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. Journal of Family Practice . 1999;48(6):453\u2013458.", "ArticleIdList": ["10386489"]}, {"Citation": "Henderson J. W., Donatelle R. J. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Alternative Therapies in Health and Medicine . 2004;10(1):52\u201357.", "ArticleIdList": ["14727500"]}, {"Citation": "Boon H. S., Olatunde F., Zick S. M. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Women\u2019s Health . 2007;7:p. 4.", "ArticleIdList": ["PMC1851951", "17397542"]}, {"Citation": "Macmahon B., Cole P., Brown J. Etiology of human breast cancer: a review. Journal of the National Cancer Institute . 1973;50(1):21\u201342.", "ArticleIdList": ["4571238"]}, {"Citation": "Miller A. B., Bulbrook R. D. The epidemiology and etiology of breast cancer. New England Journal of Medicine . 1980;303(21):1246\u20131248.", "ArticleIdList": ["7421960"]}, {"Citation": "Pike M. C., Spicer D. V., Dahmoush L., Press M. F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiologic Reviews . 1993;15(1):17\u201330.", "ArticleIdList": ["8405201"]}, {"Citation": "Yamane K., Tateishi K., Klose R. J., et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Molecular Cell . 2007;25(6):801\u2013812.", "ArticleIdList": ["17363312"]}, {"Citation": "Hirama T., Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood . 1995;86:841\u2013854.", "ArticleIdList": ["7620180"]}, {"Citation": "K\u00fcpeli Akkol E., Gen\u00e7 Y., Karpuz B., Sobarzo-S\u00e1nchez E., Capasso R. Coumarins and coumarin-related compounds in pharmacotherapy of cancer. Cancers . 2020;12:p. 1959.", "ArticleIdList": ["PMC7409047", "32707666"]}, {"Citation": "Santamaria D., Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Frontiers in Bioscience . 2006;11:1164\u20131188.", "ArticleIdList": ["16146805"]}, {"Citation": "Lee Y. M., Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle . 2006;5:2110\u20132114.", "ArticleIdList": ["16969111"]}, {"Citation": "Al-Hussaini H., Subramanyam D., Reedijk M., Sridhar S. S. Notch signaling pathway as a therapeutic target in breast cancer. Molecular Cancer Therapeutics . 2011;10:9\u201315.", "ArticleIdList": ["20971825"]}, {"Citation": "Izrailit J., Berman H. K., Datti A., Wrana J. L., Reedijk M. High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGF\u03b2 pathways as fundamental Notch regulators in breast cancer. Proceedings of the National Academy of Sciences of the United States of America . 2013;110:1714\u20131719.", "ArticleIdList": ["PMC3562766", "23319603"]}, {"Citation": "Chen Y. J., Kuo C. D., Chen S. H., et al. Small-Molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells. PLoS One . 2012;7(5, article e37006) doi: 10.1371/journal.pone.0037006.", "ArticleIdList": ["10.1371/journal.pone.0037006", "PMC3352857", "22615870"]}, {"Citation": "Huth L., Rose M., Kloubert V., et al. BDNF is associated with SFRP1 expression in luminal and Basal-Like breast cancer cell lines and primary breast cancer tissues: a novel role in tumor suppression? PLoS One . 2014;9(7, article e102558) doi: 10.1371/journal.pone.0102558.", "ArticleIdList": ["10.1371/journal.pone.0102558", "PMC4103839", "25036590"]}, {"Citation": "Lu W., Lin C., Li Y. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/\u03b2-catenin and mTORC1 signaling in prostate and breast cancer cells. Cell Signal . 2014;26:1303\u20131309.", "ArticleIdList": ["PMC4006155", "24607787"]}, {"Citation": "Mao Y., Keller E. T., Garfield D. H., Shen K., Wang J. Stroma cells in tumor microenvironment and breast cancer. Cancer and Metastasis Reviews . 2013;32:303\u2013315.", "ArticleIdList": ["PMC4432936", "23114846"]}, {"Citation": "Nwabo Kamdje A. H., Krampera M. Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment? Blood . 2011;118:6506\u20136514.", "ArticleIdList": ["21979940"]}, {"Citation": "Nwabo Kamdje A. H., Mosna F., Bifari F., et al. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow\u2013derived mesenchymal stromal cells. Blood . 2011;118(2):380\u2013389. doi: 10.1182/blood-2010-12-326694.", "ArticleIdList": ["10.1182/blood-2010-12-326694", "21602525"]}, {"Citation": "Nwabo Kamdje A. H., Bassi G., Pacelli L., et al. Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer Journal . 2012;2:p. e73. doi: 10.1038/bcj.2012.17.", "ArticleIdList": ["10.1038/bcj.2012.17", "PMC3366070", "22829975"]}, {"Citation": "Khin S. S., Kitazawa R., Kondo T., et al. Epigenetic alteration by DNA promoter hypermethylation of genes related to transforming growth factor-\u03b2 (TGF-\u03b2) signaling in cancer. Cancers (Basel) . 2011;3:982\u2013993.", "ArticleIdList": ["PMC3756400", "24212650"]}, {"Citation": "Shoeb M. Anticancer agents from medicinal plants. Bangladesh Journal of Pharmacology . 2008;1(2):35\u201341."}, {"Citation": "Newman D. J., Cragg G. M. Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products . 2016;79(3):629\u2013661.", "ArticleIdList": ["26852623"]}, {"Citation": "Balunas M. J., Kinghorn A. D. Drug discovery from medicinal plants. Life Science . 2005;78(5):431\u2013441.", "ArticleIdList": ["16198377"]}, {"Citation": "Cragg G. M., Newman D. J. Plants as a source of anticancer agents. Journal of Ethnopharmacology . 2005;100(1-2):72\u201379.", "ArticleIdList": ["16009521"]}, {"Citation": "Somasundaram S., Edmund N. A., Moore D. T., Small G. W., Shi Y. Y., Orlowski R. Z. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Research . 2002;62(13):3868\u20133875.", "ArticleIdList": ["12097302"]}, {"Citation": "Sak K. Chemotherapy and dietary phytochemical agents. Chemotherapy Research and Practice . 2012;2012:11. doi: 10.1155/2012/282570.282570", "ArticleIdList": ["10.1155/2012/282570", "PMC3539428", "23320169"]}, {"Citation": "Cooper G. M. The Cell: A Molecular Approach . 2nd. Sunderland (MA): Sinauer Associates; 2000."}, {"Citation": "Lim S., Kaldis P. CDKs, cyclins and CKIs: roles beyond cell cycle regulation. Development . 2013;140(15):3079\u20133093.", "ArticleIdList": ["23861057"]}, {"Citation": "Morgan D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annual Review of Cell and Developmental Biology . 2007;13:261\u2013291.", "ArticleIdList": ["9442875"]}, {"Citation": "Johnson A., Skotheim J. M. Start and the restriction point. Current Opinion in Cell Biology . 2013;25(6):717\u2013723. doi: 10.1016/j.ceb.2013.07.010.", "ArticleIdList": ["10.1016/j.ceb.2013.07.010", "PMC3836907", "23916770"]}, {"Citation": "Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer . 2009;9:153\u2013166.", "ArticleIdList": ["19238148"]}, {"Citation": "Fernandes M. T., Adashek J. J., Barreto C. M. N., et al. A paradigm shift for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs Context . 2018;7, article 212555", "ArticleIdList": ["PMC6220897", "30416529"]}, {"Citation": "Asghar U., Witkiewicz A. K., Turner N. C., Knudsen E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery . 2015;14(2):130\u2013146.", "ArticleIdList": ["PMC4480421", "25633797"]}, {"Citation": "Whittaker S. R., Mallinger A., Workman P., Clarke P. A. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacology & Therapeutics . 2017;173:83\u2013105.", "ArticleIdList": ["PMC6141011", "28174091"]}, {"Citation": "Roskoski R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological Research . 2019;139:471\u2013488.", "ArticleIdList": ["30508677"]}, {"Citation": "Santarius T., Shipley J., Brewer D., Stratton M. R., Cooper C. S. A census of amplified and overexpressed human cancer genes. Nature Reviews Cancer . 2010;10(1):59\u201364.", "ArticleIdList": ["20029424"]}, {"Citation": "Kamdje A. H. N., Etet P. F. S., Vecchio L., Muller J. M., Krampera M., Lukong K. E. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cellular Signalling . 2014;26(12):2843\u20132856.", "ArticleIdList": ["25093804"]}, {"Citation": "Sutherland R. L., Musgrove E. A. Cyclins and breast cancer. Journal of Mammary Gland Biology and Neoplasia . 2004;9(1):95\u2013104.", "ArticleIdList": ["15082921"]}, {"Citation": "Schwaederl\u00e9 M., Daniels G. A., Piccioni D. E., et al. Cyclin alterations in diverse cancers: outcome and co-amplification network. Oncotarget . 2015;6(5):3033\u20133042.", "ArticleIdList": ["PMC4413635", "25596748"]}, {"Citation": "Aaltonen K., Amini R. M., Heikkil\u00e4 P., et al. High cyclin B1 expression is associated with poor survival in breast cancer. British Journal of Cancer . 2009;100(7):1055\u20131060.", "ArticleIdList": ["PMC2669992", "19293801"]}, {"Citation": "Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature . 1994;369(6482):669\u2013671.", "ArticleIdList": ["8208295"]}, {"Citation": "Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature . 2001;411(6841):1017\u20131021. doi: 10.1038/35082500.", "ArticleIdList": ["10.1038/35082500", "11429595"]}, {"Citation": "Kontomanolis E. N., Kalagasidou S., Pouliliou S., et al. The Notch pathway in breast cancer progression. The Scientific World Journal . 2018;2018:11. doi: 10.1155/2018/2415489.2415489", "ArticleIdList": ["10.1155/2018/2415489", "PMC6077551", "30111989"]}, {"Citation": "Lamy M., Ferreira A., Dias J. S., Braga S., Silva G., Barbas A. Notch-out for breast cancer therapies. New Biotechnology . 2017;39(Part B):215\u2013221.", "ArticleIdList": ["28842360"]}, {"Citation": "Nowell C. S., Radtke F. Notch as a tumour suppressor. Nature Reviews Cancer . 2017;17(3):145\u2013159.", "ArticleIdList": ["28154375"]}, {"Citation": "Acar A., Sim\u00f5es B. M., Clarke B. B., Brennan K. A role for Notch signalling in breast cancer and endocrine resistance. Stem Cells International . 2016;2016:6. doi: 10.1155/2016/2498764.2498764", "ArticleIdList": ["10.1155/2016/2498764", "PMC4736972", "26880941"]}, {"Citation": "Logeat F., Bessia C., Brou C., et al. The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proceedings of the National Academy of Sciences of the United States of America . 1998;95(14):8108\u20138112.", "ArticleIdList": ["PMC20937", "9653148"]}, {"Citation": "Gordon W. R., Vardar-Ulu D., Histen G., Sanchez-Irizarry C., Aster J. C., Blacklow S. C. Structural basis for autoinhibition of Notch. Nature Structural & Molecular Biology . 2007;14(4):295\u2013300. doi: 10.1038/nsmb1227.", "ArticleIdList": ["10.1038/nsmb1227", "17401372"]}, {"Citation": "Shimizu K., Chiba S., Kumano K., et al. Mouse Jagged1 physically interacts with Notch2 and other Notch receptors. Assessment by quantitative methods. Journal of Biological Chemistry . 1999;274(46):32961\u201332969.", "ArticleIdList": ["10551863"]}, {"Citation": "Parks A. L., Stout J. R., Shepard S. B., et al. Structure function analysis of delta trafficking, receptor binding and signaling in Drosophila. Genetics . 2006;174(4):1947\u20131961. doi: 10.1534/genetics.106.061630.", "ArticleIdList": ["10.1534/genetics.106.061630", "PMC1698634", "17028337"]}, {"Citation": "D'Souza B., Miyamoto A., Weinmaster G. The many facets of Notch ligands. Oncogene . 2008;27(38):5148\u20135167.", "ArticleIdList": ["PMC2791526", "18758484"]}, {"Citation": "Ellisen L. W., Bird J., West D. C., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell . 1991;66(4):649\u2013661.", "ArticleIdList": ["1831692"]}, {"Citation": "Inder S., O'Rourke S., McDermott N., et al. The Notch-3 receptor: a molecular switch to tumorigenesis? Cancer Treatment Reviews . 2017;60:69\u201376.", "ArticleIdList": ["28889086"]}, {"Citation": "Weng A. P., Ferrando A. A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science . 2004;306(5694):269\u2013271.", "ArticleIdList": ["15472075"]}, {"Citation": "Krishna B. M., Jana S., Singhal J., et al. Notch signaling in breast cancer: from pathway analysis to therapy. Cancer Letters . 2019;461:123\u2013131.", "ArticleIdList": ["PMC9003668", "31326555"]}, {"Citation": "Reedijk M., Odorcic S., Chang L., et al. High level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research . 2005;65(18):8530\u20138537.", "ArticleIdList": ["16166334"]}, {"Citation": "Dickson B. C., Mulligan A. M., Zhang H., et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Modern Pathology . 2007;20(6):685\u2013693. doi: 10.1038/modpathol.3800785.", "ArticleIdList": ["10.1038/modpathol.3800785", "17507991"]}, {"Citation": "Xing F., Okuda H., Watabe M., et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene . 2011;30(39):4075\u20134086.", "ArticleIdList": ["PMC3145824", "21499308"]}, {"Citation": "Kontomanolis E., Panteliadou M., Giatromanolaki A., et al. Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis. Medical Oncology . 2014;31(5):p. 945. doi: 10.1007/s12032-014-0945-0.", "ArticleIdList": ["10.1007/s12032-014-0945-0", "24696220"]}, {"Citation": "Leong K. G., Niessen K., Kulic I., et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. The Journal of Experimental Medicine . 2007;204(12):2935\u20132948.", "ArticleIdList": ["PMC2118507", "17984306"]}, {"Citation": "Stylianou S., Clarke R. B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Research . 2006;66(3):1517\u20131525.", "ArticleIdList": ["16452208"]}, {"Citation": "Kiaris H., Politi K., Grimm L. M., et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. The American Journal of Pathology . 2004;165(2):695\u2013705.", "ArticleIdList": ["PMC1618582", "15277242"]}, {"Citation": "Yamaguchi N., Oyama T., Ito E., et al. Notch3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Research . 2008;68(6):1881\u20131888.", "ArticleIdList": ["18339869"]}, {"Citation": "Chen C. F., Dou X. W., Liang Y. K., et al. Notch3 overexpression causes arrest of cell cycle progression by inducing Cdh1 expression in human breast cancer cells. Cell Cycle . 2016;15(3):432\u2013440.", "ArticleIdList": ["PMC4943684", "26694515"]}, {"Citation": "Kumar S., Srivastav R. K., Wilkes D. W., et al. Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. Oncogene . 2019;38(12):2092\u20132107.", "ArticleIdList": ["PMC6756232", "30442981"]}, {"Citation": "Sales-Dias J., Silva G., Lamy M., Ferreira A., Barbas A. The Notch ligand DLL1 exerts carcinogenic features in human breast cancer cells. PLoS One . 2019;14(5, article e0217002)", "ArticleIdList": ["PMC6527237", "31107884"]}, {"Citation": "Mittal S., Sharma A., Balaji S. A., et al. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. Molecular Cancer Therapeutics . 2014;13(12):3198\u20133209.", "ArticleIdList": ["PMC4258404", "25253780"]}, {"Citation": "Dai J., Ma D., Zang S., et al. Cross-talk between Notch and EGFR signaling in human breast cancer cells. Cancer Investigation . 2009;27(5):533\u2013540.", "ArticleIdList": ["19219656"]}, {"Citation": "Osipo C., Patel P., Rizzo P., et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma secretase inhibitor. Oncogene . 2008;27(37):5019\u20135032.", "ArticleIdList": ["18469855"]}, {"Citation": "Farnie G., Willan P. M., Clarke R. B., Bundred N. J. Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS One . 2013;8(2, article e56840)", "ArticleIdList": ["PMC3572946", "23457626"]}, {"Citation": "Rizzo P., Miao H., D'Souza G., et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests nov-el therapeutic approaches. Cancer Research . 2008;68(13):5226\u20135235.", "ArticleIdList": ["PMC4445363", "18593923"]}, {"Citation": "Soares R., Balogh G., Guo S., Gartner F., Russo J., Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Molecular Endocrinology . 2004;18(9):2333\u20132343.", "ArticleIdList": ["15192074"]}, {"Citation": "Steinhaeuser S. S., Morera E., Budkova Z., et al. ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion. Laboratory Investigation . 2020;100(7):928\u2013944.", "ArticleIdList": ["32203150"]}, {"Citation": "Meurette O., Stylianou S., Rock R., Collu G. M., Gilmore A. P., Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Research . 2009;69(12):5015\u20135022.", "ArticleIdList": ["19491273"]}, {"Citation": "Zhu H., Bhaijee F., Ishaq N., et al. Correlation of Notch1, pAKT and nuclear NF-\u03baB expression in triple negative breast cancer. American Journal of Cancer Research . 2013;3(2):230\u2013239.", "ArticleIdList": ["PMC3623841", "23593544"]}, {"Citation": "Papadakos K. S., Bartoschek M., Rodriguez C., et al. Cartilage Oligo-meric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling. Matrix Biology . 2019;81:107\u2013121.", "ArticleIdList": ["30502484"]}, {"Citation": "McCubrey J. A., Davis N. M., Abrams S. L., et al. Targeting breast cancer initiating cells: advances in breast cancer research and therapy. Advances in Biological Regulation . 2014;56:81\u2013107.", "ArticleIdList": ["24913694"]}, {"Citation": "Dontu G., Jackson K. W., McNicholas E., Kawamura M. J., Abdallah W. M., Wicha M. S. Role of Notch signaling in cell fate determination of human mammary stem/progenitor cells. Breast Cancer Research . 2004;6(6):R605\u2013R615.", "ArticleIdList": ["PMC1064073", "15535842"]}, {"Citation": "Farnie G., Clarke R. B., Spence K., et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. Journal of the National Cancer Institute . 2007;99(8):616\u2013627.", "ArticleIdList": ["17440163"]}, {"Citation": "Sansone P., Storci G., Giovannini C., et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells . 2007;25(3):807\u2013815.", "ArticleIdList": ["17158237"]}, {"Citation": "Suman S., Das T. P., Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. British Journal of Cancer . 2013;109(10):2587\u20132596.", "ArticleIdList": ["PMC3833225", "24129237"]}, {"Citation": "Giuli M. V., Giuliani E., Screpanti I., Bellavia D., Checquolo S. Notch signaling activation as a hallmark for triple-negative breast bancer subtype. Journal of Oncology . 2019;2019:15. doi: 10.1155/2019/8707053.8707053", "ArticleIdList": ["10.1155/2019/8707053", "PMC6657611", "31379945"]}, {"Citation": "Mass\u00e9 J., Truntzer C., Boidot R., et al. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations. Modern Pathology . 2020;33(6):1041\u20131055.", "ArticleIdList": ["31857685"]}, {"Citation": "Valcourt D. M., Dang M. N., Scully M. A., Day E. S. Nanoparticle-mediated co delivery of Notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer. ACS Nano . 2020;14(3):3378\u20133388.", "ArticleIdList": ["PMC7098846", "32083466"]}, {"Citation": "Valcourt D. M., Day E. S. Dual regulation of mir-34a and notch signaling in triple-negative breast cancer by antibody/mirna nanocarriers. Molecular Therapy-Nucleic Acids . 2020;21:290\u2013298.", "ArticleIdList": ["PMC7332498", "32622330"]}, {"Citation": "Alkaraki A., Alshaer W., Wehaibi S., et al. Enhancing chemosensitivity of wild type and drug resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and \u03b2-catenin genes. Breast Cancer . 2020;27(5):989\u2013998.", "ArticleIdList": ["32328816"]}, {"Citation": "Sardesai S., Badawi M., Mrozek E., et al. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Investigational New Drugs . 2020;38(5):1400\u20131410.", "ArticleIdList": ["PMC7955776", "31953695"]}, {"Citation": "Logan C. Y., Nusse R. The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology . 2004;20:781\u2013810.", "ArticleIdList": ["15473860"]}, {"Citation": "Dang D., Peng Y. Roles of p53 and p16 in triple-negative breast cancer. Breast Cancer Management . 2013;2(6):537\u2013544."}, {"Citation": "Ayyanan A., Civenni G., Ciarloni L., et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proceedings of the National Academy of Sciences . 2006;103(10):3799\u20133804.", "ArticleIdList": ["PMC1450156", "16501043"]}, {"Citation": "Chen M. S., Woodward W. A., Behbod F., et al. Wnt/\u03b2-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. Journal of Cell Science . 2007;120(3):468\u2013477.", "ArticleIdList": ["17227796"]}, {"Citation": "Zhou X. L., Qin X. R., Zhang X. D., Ye L. H. Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/\u03b2-catenin signaling. Acta Pharmacologica Sinica . 2010;31(2):202\u2013210.", "ArticleIdList": ["PMC4002845", "20139903"]}, {"Citation": "Lamb R., Ablett M. P., Spence K., Landberg G., Sims A. H., Clarke R. B. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One . 2013;8(7, article e67811)", "ArticleIdList": ["PMC3701602", "23861811"]}, {"Citation": "Wagener C., Stocking C., M\u00fcller O. Cancer Signaling: From Molecular Biology to Targeted Therapy . John Wiley & Sons; 2016."}, {"Citation": "Riaz S. K., Ke Y., Wang F., Kayani M. A., Malik M. F. A. Influence of SHH/GLI1 axis on EMT mediated migration and invasion of breast cancer cells. Scientific Reports . 2019;9(1):1\u201313.", "ArticleIdList": ["PMC6488587", "31036836"]}, {"Citation": "Zhao Y., Tong C., Jiang J. Hedgehog regulates smoothened activity by inducing a conformational switch. Nature . 2007;450(7167):252\u2013258.", "ArticleIdList": ["17960137"]}, {"Citation": "Hui M., Cazet A., Nair R., Watkins D. N., O'Toole S. A., Swarbrick A. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Research . 2013;15(2):1\u201314.", "ArticleIdList": ["PMC3672663", "23547970"]}, {"Citation": "O'Toole S. A., Machalek D. A., Shearer R. F., et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Research . 2011;71(11):4002\u20134014.", "ArticleIdList": ["21632555"]}, {"Citation": "Garc\u00eda-Zaragoza E., P\u00e9rez-Tavarez R., Ballester A., et al. Intraepithelial paracrine Hedgehog signaling induces the expansion of ciliated cells that express diverse progenitor cell markers in the basal epithelium of the mouse mammary gland. Developmental Biology . 2012;372(1):28\u201344.", "ArticleIdList": ["23000969"]}, {"Citation": "Fiaschi M., Rozell B., Bergstr\u00f6m \u00c5., Toftg\u00e5rd R., Kleman M. I. Targeted expression of GLI1 in the mammary gland dis-rupts pregnancy-induced maturation and causes lactation failure. Journal of Biological Chemistry . 2007;282(49):36090\u201336101.", "ArticleIdList": ["17928300"]}, {"Citation": "Jeng K. S., Sheen I. S., Jeng W. J., Yu M. C., Hsiau H. I., Chang F. Y. High expression of Sonic Hedgehog signaling pathway genes indicates a risk of recurrence of breast carcinoma. OncoTargets and Therapy . 2014;7:p. 79.", "ArticleIdList": ["PMC3883580", "24403838"]}, {"Citation": "Aubele M., Auer G., Walch A. K., et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long term survival in breast carcinomas. British Journal of Cancer . 2007;96(5):801\u2013807.", "ArticleIdList": ["PMC2360069", "17299391"]}, {"Citation": "Miah S., Martin A., Lukong K. E. Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo. Oncogenesis . 2012;1(5):e11\u2013e11.", "ArticleIdList": ["PMC3412638", "23552639"]}, {"Citation": "Ikeda O., Miyasaka Y., Sekine Y., et al. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochemical and Biophysical Research Communications . 2009;384(1):71\u201375.", "ArticleIdList": ["19393627"]}, {"Citation": "Shen C. H., Chen H. Y., Lin M. S., et al. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Research . 2008;68(19):7779\u20137787.", "ArticleIdList": ["18829532"]}, {"Citation": "Ostrander J. H., Daniel A. R., Lofgren K., Kleer C. G., Lange C. A. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Research . 2007;67(9):4199\u20134209.", "ArticleIdList": ["17483331"]}, {"Citation": "Kamalati T., Jolin H. E., Mitchell P. J., et al. Brk, a breast tumor derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. Journal of Biological Chemistry . 1996;271(48):30956\u201330963.", "ArticleIdList": ["8940083"]}, {"Citation": "Shah S., Chen B. Testing for HER2 in breast cancer: a continuing evolution. Pathology Research International . 2011;2011:16. doi: 10.4061/2011/903202.903202", "ArticleIdList": ["10.4061/2011/903202", "PMC3005907", "21188214"]}, {"Citation": "Cho H. S., Mason K., Ramyar K. X., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature . 2003;421(6924):756\u2013760. doi: 10.1038/nature01392.", "ArticleIdList": ["10.1038/nature01392", "12610629"]}, {"Citation": "Ts\u00e9 C., Gauchez A. S., Jacot W., Lamy P. J. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treatment Reviews . 2012;38(2):133\u2013142. doi: 10.1016/j.ctrv.2011.03.008.", "ArticleIdList": ["10.1016/j.ctrv.2011.03.008", "21549508"]}, {"Citation": "Nunes R. A., Harris L. N. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clinical Breast Cancer . 2002;3(2):125\u2013135.", "ArticleIdList": ["12123536"]}, {"Citation": "Jeong J. H., An J. Y., Kwon Y. T., Li L. Y., Lee Y. J. Quercetin-induced ubiquitination and down-regulation of Her-2/neu. Journal of Cellular Biochemistry . 2008;105(2):585\u2013595.", "ArticleIdList": ["PMC2575035", "18655187"]}, {"Citation": "Lee C. C., Yang H. L., Way T. D., et al. Inhibition of cell growth and induction of apoptosis by Antrodia camphorata in HER-2/neu-overexpressing breast cancer cells through the induction of ROS, depletion of HER-2/neu, and disruption of the PI3K/Akt signaling pathway. Evidence-Based Complementary and Alternative Medicine . 2012;2012:15. doi: 10.1155/2012/702857.702857", "ArticleIdList": ["10.1155/2012/702857", "PMC3371823", "22701509"]}, {"Citation": "Gali-Muhtasib H. Cyclin-dependent kinase inhibitors from natural sources: Recent advances and future prospects for cancer treatment. Advances in Phytomedicine . 2006;2:155\u2013167."}, {"Citation": "Li A., Blow J. J. The origin of CDK regulation. Nature Cell Biology . 2011;3(8):E182\u2013E184.", "ArticleIdList": ["PMC3604809", "11483974"]}, {"Citation": "Bai J., Li Y., Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biology & Medicine . 2017;14(4):p. 348. doi: 10.20892/j.issn.2095-3941.2017.0033.", "ArticleIdList": ["10.20892/j.issn.2095-3941.2017.0033", "PMC5785171", "29372101"]}, {"Citation": "Laderian B., Fojo T. CDK4/6 inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. Seminars in Oncology . 2017;44(6):395\u2013403.", "ArticleIdList": ["29935901"]}, {"Citation": "Malumbres M. Cell cycle-based therapies move forward. Cancer Cell . 2012;22(4):419\u2013420.", "ArticleIdList": ["23079651"]}, {"Citation": "Sawai C. M., Freund J., Oh P., et al. Therapeutic targeting of the cyclin D3: CDK4/6 complex in T cell leukemia. Cancer Cell . 2012;22(4):452\u2013465. doi: 10.1016/j.ccr.2012.09.016.", "ArticleIdList": ["10.1016/j.ccr.2012.09.016", "PMC3493168", "23079656"]}, {"Citation": "S\u00e1nchez-Mart\u00ednez C., Lallena M. J., Sanfeliciano S. G., de Dios A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015\u20132019) Bioorganic & Medicinal Chemistry Letters . 2019;29(20, article 126637) doi: 10.1016/j.bmcl.2019.126637.", "ArticleIdList": ["10.1016/j.bmcl.2019.126637", "31477350"]}, {"Citation": "Yamamoto S., Schulze K. L., Bellen H. J. Introduction to Notch signaling . New York, NY: Humana Press; 2014.", "ArticleIdList": ["25053477"]}, {"Citation": "Braune E. B., Lendahl U. Notch-a goldilocks signaling pathway in disease and cancer therapy. Discovery Medicine . 2016;21(115):189\u2013196.", "ArticleIdList": ["27115169"]}, {"Citation": "Espinoza I., Miele L. Notch inhibitors for cancer treatment. Pharmacology & Therapeutics . 2013;139(2):95\u2013110.", "ArticleIdList": ["PMC3732476", "23458608"]}, {"Citation": "Jamdade V. S., Sethi N., Mundhe N. A., Kumar P., Lahkar M., Sinha N. Therapeutic targets of triple-negative breast cancer: a review. British Journal of Pharmacology . 2015;172(17):4228\u20134237. doi: 10.1111/bph.13211.", "ArticleIdList": ["10.1111/bph.13211", "PMC4556464", "26040571"]}, {"Citation": "Zhang Y., Xie Z. Y., Guo X. T., Xiao X. H., Xiong L. X. Notch and breast cancer metastasis: current knowledge, new sights and targeted therapy. Oncology Letters . 2019;18(3):2743\u20132755.", "ArticleIdList": ["PMC6704289", "31452752"]}, {"Citation": "Stoeck A., Lejnine S., Truong A., et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discovery . 2014;4(10):1154\u20131167.", "ArticleIdList": ["PMC4184927", "25104330"]}, {"Citation": "Kamdje A. H. N., Etet P. F. S., Vecchio L., Muller J. M., Krampera M., Lukong K. E. Signaling pathways in breast cancer: therapeutic tar-geting of the microenvironment. Cell Signal . 2014;26:2843\u20132856.", "ArticleIdList": ["25093804"]}, {"Citation": "Bhatt A. P., Bhende P. M., Sin S. H., Roy D., Dittmer D. P., Damania B. Damania, Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood, The Journal of the American Society of Hematology . 2010;115(22):4455\u20134463.", "ArticleIdList": ["PMC2881502", "20299510"]}, {"Citation": "Wu P., Hu Y. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Current Medicinal Chemistry . 2010;17:4326\u20134341.", "ArticleIdList": ["20939811"]}, {"Citation": "Saldanha S. N., Tollefsbol T. O. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical out-comes. Journal of Oncology . 2012;2012:23. doi: 10.1155/2012/192464.92464", "ArticleIdList": ["10.1155/2012/192464", "PMC3236518", "22187555"]}, {"Citation": "Liao G.-S., Apaya M. K., Shyur L.-F. Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. Evidence-Based Complementary and Alternative Medicine . 2013;2013:17. doi: 10.1155/2013/437948.437948", "ArticleIdList": ["10.1155/2013/437948", "PMC3694462", "23840256"]}, {"Citation": "Li F., Li S., Li H. B., Deng G. F., Ling W. H., Xu X. R. Antiproliferative activities of tea and herbal infusions. Food & Function . 2013;4(4):530\u2013538.", "ArticleIdList": ["23307138"]}, {"Citation": "Zheng J., Zhou Y., Li Y., Xu D.-P., Li S., Li H.-B. Spices for prevention and treatment of cancers. Nutrients . 2016;8(8):p. 495.", "ArticleIdList": ["PMC4997408", "27529277"]}, {"Citation": "Zhou Y., Zheng J., Li Y., et al. Natural polyphenols for prevention and treatment of cancer. Nutrients . 2016;8(8):p. 515.", "ArticleIdList": ["PMC4997428", "27556486"]}, {"Citation": "Grosso G., Bella F., Godos J., et al. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutrition Reviews . 2017;75(6):405\u2013419.", "ArticleIdList": ["28969358"]}, {"Citation": "Thakur V. S., Deb G., Babcook M. A., Gupta S. Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. The AAPS Journal . 2014;16(1):151\u2013163.", "ArticleIdList": ["PMC3889536", "24307610"]}, {"Citation": "Khan S. I., Aumsuwan P., Khan I. A., Walker L. A., Dasmahapatra A. K. Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chemical Research in Toxicology . 2012;25(1):61\u201373.", "ArticleIdList": ["21992498"]}, {"Citation": "Landis-Piwowar K. R., Milacic V., Dou Q. P. Relationship between the methylation status of dietary flavonoids and their growth inhibitory and apoptosis-inducing activities in human cancer cells. Journal of Cellular Biochemistry . 2008;105(2):514\u2013523.", "ArticleIdList": ["PMC2574743", "18636546"]}, {"Citation": "Aggarwal R., Jha M., Shrivastava A., Jha A. K. Natural compounds: role in reversal of epigenetic changes. Biochemistry (Moscow) . 2015;80(8):972\u2013989.", "ArticleIdList": ["26547065"]}, {"Citation": "Ko E., Moon A. Natural products for chemoprevention of breast cancer. Journal of Cancer Prevention . 2015;20(4):223\u2013231.", "ArticleIdList": ["PMC4699749", "26734584"]}, {"Citation": "Lephart E. D. Modulation of aromatase by phytoestrogens. Enzyme Research . 2015;2015:11. doi: 10.1155/2015/594656.594656", "ArticleIdList": ["10.1155/2015/594656", "PMC4699002", "26798508"]}, {"Citation": "Yarla N. S., Bishayee A., Sethi G., et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Seminars in Cancer Biology . 2016;40:48\u201381. doi: 10.1016/j.semcancer.2016.02.001.", "ArticleIdList": ["10.1016/j.semcancer.2016.02.001", "26853158"]}, {"Citation": "Cuendet M., Pezzuto J. M. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabolism and Drug Interactions . 2000;17(1-4):109\u2013157.", "ArticleIdList": ["11201293"]}, {"Citation": "Wang D., Dubois R. N. Eicosanoids and cancer. Nature Reviews Cancer . 2010;10(3):181\u2013193.", "ArticleIdList": ["PMC2898136", "20168319"]}, {"Citation": "Denkert C., Winzer K. J., M\u00fcller B. M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer . 2003;97(12):2978\u20132987.", "ArticleIdList": ["12784332"]}, {"Citation": "Ranger G. S., Thomas V., Jewell A., Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Research . 2004;24(4):2349\u20132351.", "ArticleIdList": ["15330183"]}, {"Citation": "Stasinopoulos I., O\u2019Brien D. R., Wildes F., Glunde K., Bhujwalla Z. M. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Molecular Cancer Research . 2007;5(5):435\u2013442. doi: 10.1158/1541-7786.mcr-07-0010.", "ArticleIdList": ["10.1158/1541-7786.mcr-07-0010", "17510310"]}, {"Citation": "Sun S., Hail N., Lotan R. Apoptosis as a novel target for cancer chemoprevention. Journal of the National Cancer Institute . 2004;96(9):662\u2013672.", "ArticleIdList": ["15126603"]}, {"Citation": "Dall\u2019acqua S. Natural products as antimitotic agents. Current Topics in Medicinal Chemistry . 2014;14(20):2272\u20132285.", "ArticleIdList": ["25434355"]}, {"Citation": "Liu H., Chen X., Sun J., et al. The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. Medicine . 2014;93(25):p. e164. doi: 10.1097/MD.0000000000000164.", "ArticleIdList": ["10.1097/MD.0000000000000164", "PMC4616381", "25437030"]}, {"Citation": "Mitra S., Dash R. Natural products for the management and prevention of breast cancer. Evidence-Based Complementary and Alternative Medicine . 2018;2018:23. doi: 10.1155/2018/8324696.8324696", "ArticleIdList": ["10.1155/2018/8324696", "PMC5846366", "29681985"]}, {"Citation": "Iqbal J., Abbasi B., Mahmood T., Kanwal S., Ali B., Shah S. Plant-derived anticancer agents: a green anticancer approach. Asian Pacific Journal of Tropical Biomedicine . 2017;7(12):1129\u20131150."}, {"Citation": "Mirahmadi M., Azimi-Hashemi S., Saburi E., Kamali H., Pishbin M., Hadizadeh F. Potential inhibitory effect of lycopene on prostate cancer. Biomedicine & Pharmacotherapy . 2020;129, article 110459 doi: 10.1016/j.biopha.2020.110459.", "ArticleIdList": ["10.1016/j.biopha.2020.110459", "32768949"]}, {"Citation": "Miller N. J., Sampson J., Candeias L. P., Bramley P. M., Rice-Evans C. A. Antioxidant activities of carotenes and xanthophylls. FEBS Letters . 1996;384:240\u2013246. doi: 10.1016/0014-5793(96)00323-7.", "ArticleIdList": ["10.1016/0014-5793(96)00323-7", "8617362"]}, {"Citation": "Teodoro A. J., Oliveira F. L., Martins N. B., Maia Gde A., Martucci R. B., Borojevic R. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell International . 2012;12(1):p. 36.", "ArticleIdList": ["PMC3492052", "22866768"]}, {"Citation": "Peng S. J., Li J., Zhou Y., et al. In vitro effects and mechanisms of lycopene in MCF-7 human breast cancer cells. Genetics and Molecular Research . 2017;16(2)", "ArticleIdList": ["28407181"]}, {"Citation": "Gloria N. F., Soares N., Brand C., Oliveira F. L., Borojevic R., Teodoro A. J. Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. Anticancer Research . 2014;34(3):1377\u20131386.", "ArticleIdList": ["24596385"]}, {"Citation": "Nahum A., Hirsch K., Danilenko M., et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene . 2001;20(26):3428\u20133436.", "ArticleIdList": ["11423993"]}, {"Citation": "Nahum A., Zeller L., Danilenko M., et al. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. European Journal of Nutrition . 2006;45:275\u2013282.", "ArticleIdList": ["16565789"]}, {"Citation": "Karas M., Amir H., Fishman D., et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutrition and Cancer . 2000;36(1):101\u2013111.", "ArticleIdList": ["10798222"]}, {"Citation": "Holzapfel N. P., Holzapfel B. M., Theodoropoulos C., et al. Lycopene's effects on cancer cell functions within monolayer and spheroid cultures. Nutrition and Cancer . 2016;68(2):350\u2013363.", "ArticleIdList": ["27015041"]}, {"Citation": "Koh M. S., Hwang J. S., Moon A. R. Lycopene inhibits proliferation, invasion and migration of human breast cancer cells. Biomolecules & Therapeutics . 2010;18(1):92\u201398."}, {"Citation": "Assar E. A., Vidalle M. C., Chopra M., Hafizi S. Lycopene acts through inhibition of I\u03baB kinase to suppress NF-\u03baB signaling in human prostate and breast cancer cells. Tumor Biology . 2016;37(7):9375\u20139385.", "ArticleIdList": ["26779636"]}, {"Citation": "Huang H. C., Lin C. L., Lin J. K. 1,2,3,4,6-Penta-O-galloyl-\u03b2-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. Journal of Agricultural and Food Chemistry . 2011;59(12):6765\u20136775.", "ArticleIdList": ["21598989"]}, {"Citation": "Takeshima M., Ono M., Higuchi T., Chen C., Hara T., Nakano S. Anti-proliferative and apoptosis inducing activity of lycopene against three subtypes of human breast cancer cell lines. Cancer Science . 2014;105(3):252\u2013257.", "ArticleIdList": ["PMC4317951", "24397737"]}, {"Citation": "Uppala P. T., Dissmore T., Lau B. H., Andacht T., Rajaram S. Selective inhibition of cell proliferation by lycopene in MCF-7 breast cancer cells in vitro: a proteomic analysis. Phytotherapy Research . 2013;27(4):595\u2013601.", "ArticleIdList": ["22718574"]}, {"Citation": "Chalabi N., Le Corre L., Maurizis J. C., Bignon Y. J., Bernard-Gallon D. J. The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression. European Journal of Cancer . 2004;4(11):1768\u20131775.", "ArticleIdList": ["15251168"]}, {"Citation": "King-Batoon A., Leszczynska J. M., Klein C. B. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environmental and Molecular Mutagenesis . 2008;49(1):36\u201345.", "ArticleIdList": ["18181168"]}, {"Citation": "Chalabi N., Delort L., Le Corre L., Satih S., Bignon Y. J., Bernard-Gallon D. Gene signature of breast cancer cell lines treated with lycopene. Pharmacogenomics . 2006;7(5):663\u2013672.", "ArticleIdList": ["16886892"]}, {"Citation": "Chalabi N., Satih S., Delort L., Bignon Y. J., Bernard-Gallon D. J. Expression profiling by whole genome microarray hybridization reveals differential gene expression in breast cancer cell lines after lycopene exposure. Biochimica et Biophysica Acta . 2007;1769(2):124\u2013130.", "ArticleIdList": ["17321611"]}, {"Citation": "Boulos J. C., Rahama M., Hegazy M. E. F., Efferth T. Shikonin derivatives for cancer prevention and therapy. Cancer Letters . 2019;459:248\u2013267.", "ArticleIdList": ["31132429"]}, {"Citation": "And\u00fajar I., R\u00edos J. L., Giner R. M., Recio M. C. Pharmacological properties of shikonin-a review of literature since 2002. Planta Medica . 2013;79(18):1685\u20131697.", "ArticleIdList": ["24155261"]}, {"Citation": "Thakur R., Trivedi R., Rastogi N., Singh M., Mishra D. P. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Scientific Reports . 2015;5, article 10194", "ArticleIdList": ["PMC4431480", "25973915"]}, {"Citation": "Wei Y., Li M., Cui S., et al. Shikonin inhibits the proliferation of human breast cancer cells by reducing tumor-derived exosomes. Molecules . 2016;21(6):p. 777.", "ArticleIdList": ["PMC6274101", "27322220"]}, {"Citation": "Lin K. H., Huang M. Y., Cheng W. C., et al. RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment. Scientific Reports . 2018;8(1):p. 2672.", "ArticleIdList": ["PMC5805692", "29422643"]}, {"Citation": "Hou Y., Guo T., Wu C., He X., Zhao M. Effect of shikonin on human breast cancer cells proliferation and apoptosis in vitro. Yakugaku Zasshi . 2006;126(12):1383\u20131386.", "ArticleIdList": ["17139164"]}, {"Citation": "Chen Y., Chen Z. Y., Chen L., et al. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3\u03b2-regulated suppression of \u03b2-catenin signaling. Biochemical Pharmacology . 2019;166:33\u201345.", "ArticleIdList": ["31071331"]}, {"Citation": "Jang S. Y., Lee J. K., Jang E. H., Jeong S. Y., Kim J. H. Shikonin blocks migration and invasion of human breast cancer cells through inhibition of matrix metalloproteinase-9 activation. Oncology Reports . 2014;31(6):2827\u20132833.", "ArticleIdList": ["24789371"]}, {"Citation": "Xu J., Koizumi K., Liu M., et al. Shikonin induces an antitumor effect on murine mammary cancer via p38 dependent apoptosis. Oncology Reports . 2019;41(3):2020\u20132026.", "ArticleIdList": ["30664166"]}, {"Citation": "Shahsavari Z., Karami-Tehrani F., Salami S. Shikonin \u0131nduced necroptosis via reactive oxygen species in the t-47d breast cancer cell line. Asian Pacific Journal of Cancer Prevention . 2015;16(16):7261\u20137266.", "ArticleIdList": ["26514521"]}, {"Citation": "Shahsavari Z., Karami-Tehrani F., Salami S., Ghasemzadeh M. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway. Tumor Biology . 2016;37(4):4479\u20134491.", "ArticleIdList": ["26496737"]}, {"Citation": "Shahsavari Z., Karami-Tehrani F., Salami S. Targeting cell necroptosis and apoptosis \u0131nduced by shikonin via receptor \u0131nteracting protein kinases in estrogen receptor positive breast cancer cell line, MCF-7. Anti-Cancer Agents in Medicinal Chemistry . 2018;18(2):245\u2013254.", "ArticleIdList": ["28933271"]}, {"Citation": "Yao Y., Zhou Q. A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells. Breast Cancer Research and Treatment . 2010;121(1):233\u2013240.", "ArticleIdList": ["19760501"]}, {"Citation": "Yao Y., Brodie A. M., Davidson N. E., Kensler T. W., Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Research and Treatment . 2010;124(2):585\u2013591.", "ArticleIdList": ["PMC3417311", "20623181"]}, {"Citation": "Zhang Y., Qian R. Q., Li P. P. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells. Cancer Letters . 2009;284(1):47\u201354.", "ArticleIdList": ["19419812"]}, {"Citation": "Yang Y., Gao W., Tao S., et al. ER-mediated anti-tumor effects of shikonin on breast cancer. European Journal of Pharmacology . 2019;863, article 172667 doi: 10.1016/j.ejphar.2019.172667.", "ArticleIdList": ["10.1016/j.ejphar.2019.172667", "31545985"]}, {"Citation": "Gernapudi R., Yao Y., Zhang Y., et al. Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early stage breast cancer. Breast Cancer Research and Treatment . 2015;150(3):685\u2013695.", "ArticleIdList": ["PMC4385483", "25783182"]}, {"Citation": "Kaboli P. J., Khoshkbejari M. A., Mohammadi M., et al. Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer contradictory effects and future perspectives. Biomedicine & Pharmacotherapy . 2020;121, article 109635 doi: 10.1016/j.biopha.2019.109635.", "ArticleIdList": ["10.1016/j.biopha.2019.109635", "31739165"]}, {"Citation": "Hussain A., Mohsin J., Prabhu S. A., et al. Sulforaphane inhibits growth of human breast cancer cells and augments the therapeutic index of the chemotherapeutic drug, gemcitabine. Asian Pacific Journal of Cancer Prevention . 2013;14(10):5855\u20135860.", "ArticleIdList": ["24289589"]}, {"Citation": "Lee Y. R., Noh E. M., Han J. H., et al. Sulforaphane controls TPA-induced MMP-9 expression through the NF-\u03baB signaling pathway, but not AP-1, in MCF-7 breast cancer cells. BMB Reports . 2013;46(4):201\u2013206. doi: 10.5483/BMBRep.2013.46.4.160.", "ArticleIdList": ["10.5483/BMBRep.2013.46.4.160", "PMC4133889", "23615261"]}, {"Citation": "Castro N. P., Rangel M. C., Merchant A. S., et al. Sulforaphane suppresses the growth of triple-negative breast cancer stem-like cells in vitro and in vivo. Cancer Prevention Research . 2019;12(3):147\u2013158. doi: 10.1158/1940-6207.CAPR-18-0241.", "ArticleIdList": ["10.1158/1940-6207.CAPR-18-0241", "PMC6425935", "30679159"]}, {"Citation": "Kaczy\u0144ska A., \u015awierczy\u0144ska J., Herman-Antosiewicz A. Sensitization of HER2 positive breast cancer cells to lapatinib using plants-derived isothiocyanates. Nutrition and Cancer . 2015;67(6):976\u2013986. doi: 10.1080/01635581.2015.1053498.", "ArticleIdList": ["10.1080/01635581.2015.1053498", "26134366"]}, {"Citation": "Ramirez M. C., Singletary K. Regulation of estrogen receptor alpha expression in human breast cancer cells by sulforaphane. The Journal of Nutritional Biochemistry . 2009;20(3):195\u2013201. doi: 10.1016/j.jnutbio.2008.02.002.", "ArticleIdList": ["10.1016/j.jnutbio.2008.02.002", "18602823"]}, {"Citation": "Cao S., Wang L., Zhang Z., Chen F., Wu Q., Li L. Sulforaphane-induced metabolomic responses with epigenetic changes in estrogen receptor positive breast cancer cell. FEBS Open Biol . 2018;8(12):2022\u20132034.", "ArticleIdList": ["PMC6275259", "30524952"]}, {"Citation": "Jo E. H., Kim S. H., Ahn N. S., et al. Efficacy of sulforaphane is mediated by p38 MAP kinase and caspase-7 activations in ER-positive and COX-2-expressed human breast cancer cells. European Journal of Cancer Prevention . 2007;16(6):505\u2013510. doi: 10.1097/01.cej.0000243856.97479.3b.", "ArticleIdList": ["10.1097/01.cej.0000243856.97479.3b", "18090122"]}, {"Citation": "Bagheri M., Fazli M., Saeednia S., Gholami Kharanagh M., Ahmadiankia N. Sulforaphane modulates cell migration and expression of \u03b2-catenin and epithelial mesenchymal transition markers in breast cancer cells. Iranian Journal of Public Health . 2020;49(1):77\u201385.", "ArticleIdList": ["PMC7152640", "32309226"]}, {"Citation": "Hunakova L., Sedlakova O., Cholujova D., Gronesova P., Duraj J., Sedlak J. Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphan. Neoplasma . 2009;56(6):548\u2013556.", "ArticleIdList": ["19728765"]}, {"Citation": "Kanematsu S., Uehara N., Miki H., et al. Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Research . 2010;30(9):3381\u20133390.", "ArticleIdList": ["20944112"]}, {"Citation": "Pledgie-Tracy A., Sobolewski M. D., Davidson N. E. Sulforaphane induces cell type-specific apoptosis in human breast can-cer cell lines. Molecular Cancer Therapeutics . 2007;6(3):1013\u20131021. doi: 10.1158/1535-7163.MCT-06-0494.", "ArticleIdList": ["10.1158/1535-7163.MCT-06-0494", "17339367"]}, {"Citation": "Pawlik A., Wiczk A., Kaczy\u0144ska A., Antosiewicz J., Herman-Antosiewicz A. Sulforaphane inhibits growth of phenotypically different breast cancer cells. European Journal of Nutrition . 2013;52(8):1949\u20131958. doi: 10.1007/s00394-013-0499-5.", "ArticleIdList": ["10.1007/s00394-013-0499-5", "PMC3832756", "23389114"]}, {"Citation": "Sarkar R., Mukherjee S., Biswas J., Roy M. Sulphoraphane, a naturally occurring isothiocyanate induces apoptosis in breast cancer cells by targeting heat shock proteins. Biochemical and Biophysical Research Communications . 2012;427(1):80\u201385. doi: 10.1016/j.bbrc.2012.09.006.", "ArticleIdList": ["10.1016/j.bbrc.2012.09.006", "22975350"]}, {"Citation": "Cheng A. C., Shen C. J., Hung C. M., Hsu Y. C. Sulforaphane decrease of SERTAD1 expression triggers G1/S arrest in breast cancer cells. Journal of Medicinal Food . 2019;22(5):444\u2013450.", "ArticleIdList": ["PMC6534085", "31084542"]}, {"Citation": "Sim\u00f5es B. M., Santiago-G\u00f3mez A., Chiodo C., et al. Targeting STAT3 signaling using stabilized sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer. Oncogene . 2020;39(25):4896\u20134908.", "ArticleIdList": ["PMC7299846", "32472077"]}, {"Citation": "Lewinska A., Adamczyk-Grochala J., Deregowska A., Wnuk M. Sulforaphane-induced cell cycle arrest and senescence are accompanied by DNA hypomethylation and changes in microRNA profile in breast cancer cells. Theranostics . 2017;7(14):3461\u20133477.", "ArticleIdList": ["PMC5596436", "28912888"]}, {"Citation": "Clulow J. A., Storck E. M., Lanyon-Hogg T., Kalesh K. A., Jones L. H., Tate E. W. Competition based, quantitative chemical proteomics in breast cancer cells identifies new target profiles for sulforaphane. Chemical Communications . 2017;53(37):5182\u20135185.", "ArticleIdList": ["PMC6034444", "28439590"]}, {"Citation": "Meeran S. M., Patel S. N., Tollefsbol T. O. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One . 2010;5(7, article e11457)", "ArticleIdList": ["PMC2897894", "20625516"]}, {"Citation": "Azarenko O., Okouneva T., Singletary K. W., Jordan M. A., Wilson L. Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis . 2008;29(12):2360\u20132368.", "ArticleIdList": ["PMC2639247", "18952594"]}, {"Citation": "Lewinska A., Bednarz D., Adamczyk-Grochala J., Wnuk M. Phytochemical-induced nucleolar stress results in the inhibi-tion of breast cancer cell proliferation. Redox Biology . 2017;12:469\u2013482.", "ArticleIdList": ["PMC5362140", "28334682"]}, {"Citation": "Kim H. N., Kim D. H., Kim E. H., et al. Sulforaphane inhibits phorbol ester-stimulated IKK-NF-\u03baB signaling and COX-2 expression in human mammary epithelial cells by targeting NF-\u03baB acti-vating kinase and ERK. Cancer Letters . 2014;351(1):41\u201349.", "ArticleIdList": ["24747121"]}, {"Citation": "Jackson S. J., Singletary K. W. Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis . 2004;2(2):219\u2013227.", "ArticleIdList": ["14578157"]}, {"Citation": "Cao C., Wu H., Vasilatos S. N., et al. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. International Journal of Cancer . 2018;143(6):1388\u20131401.", "ArticleIdList": ["PMC6105499", "29633255"]}, {"Citation": "Yang M., Teng W., Qu Y., Wang H., Yuan Q. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1. Breast Cancer Research and Treatment . 2016;158(2):277\u2013286.", "ArticleIdList": ["27377973"]}, {"Citation": "Cornblatt B. S., Ye L., Dinkova-Kostova A. T., et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis . 2007;28(7):1485\u20131490.", "ArticleIdList": ["17347138"]}, {"Citation": "Burnett J. P., Lim G., Li Y., et al. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. Cancer Letters . 2017;394:52\u201364.", "ArticleIdList": ["PMC8892390", "28254410"]}, {"Citation": "Bose C., Awasthi S., Sharma R., et al. Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. PLoS One . 2018;13(3, article e0193918)", "ArticleIdList": ["PMC5843244", "29518137"]}, {"Citation": "Yang F., Wang F., Liu Y., et al. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. Life Sciences . 2018;213:149\u2013157.", "ArticleIdList": ["30352240"]}, {"Citation": "Kim S. H., Park H. J., Moon D. O. Sulforaphane sensitizes human breast cancer cells to paclitaxel-induced apoptosis by downregulating the NF-\u03baB signaling pathway. Oncology Letters . 2017;13(6):4427\u20134432. doi: 10.3892/ol.2017.5950.", "ArticleIdList": ["10.3892/ol.2017.5950", "PMC5453055", "28599444"]}, {"Citation": "Milczarek M., Wiktorska K., Mielczarek L., et al. Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anti-cancer effect in MDA-MB-231 triple negative breast cancer cell line. Food and Chemical Toxicology . 2018;111:1\u20138.", "ArticleIdList": ["29104175"]}, {"Citation": "Chirumbolo S., Bj\u00f8rklund G. Sulforaphane and 5-fluorouracil synergistically inducing autophagy in breast cancer: a possible role for the Nrf2-Keap1-ARE signaling? Food and Chemical Toxicology . 2018;112:414\u2013415.", "ArticleIdList": ["29305271"]}, {"Citation": "Lubecka K., Kaufman-Szymczyk A., Fabianowska-Majewska K. Inhibition of breast cancer cell growth by the combination of clofarabine and sulforaphane involves epigenetically mediated CDKN2A upregulation. Nucleosides Nucleotides Nucleic Acids . 2018;37(5):280\u2013289.", "ArticleIdList": ["29634384"]}, {"Citation": "Pawlik A., S\u0142omi\u0144ska-Wojew\u00f3dzka M., Herman-Antosiewicz A. Sensitization of estrogen receptor positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants. European Journal of Nutrition . 2016;55(3):1165\u20131180. doi: 10.1007/s00394-015-0930-1.", "ArticleIdList": ["10.1007/s00394-015-0930-1", "PMC4819954", "26014809"]}, {"Citation": "Xue J.-P., Wang G., Zhao Z.-B., Wang Q., Shi Y. Synergistic cytotoxic effect of genistein and doxorubicin on drug-resistant human breast cancer MCF-7/Adr cells. Oncology Reports . 2014;32(4):1647\u20131653. doi: 10.3892/or.2014.3365.", "ArticleIdList": ["10.3892/or.2014.3365", "25109508"]}, {"Citation": "Charalambous C., Pitta C. A., Constantinou A. I. Equol enhances tamoxifen\u2019s anti-tumor activity by induction of caspase-mediated apoptosis inMCF-7 breast cancer cells. BMC Cancer . 2018;13:p. 238.", "ArticleIdList": ["PMC3661348", "23675643"]}, {"Citation": "McGuire K. P., Ngoubilly N., Neavyn N., Lanza-Jacoby S. 3,3\u2032-Diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. Journal of Surgical Research . 2006;132(2):208\u2013213.", "ArticleIdList": ["16580691"]}, {"Citation": "Gonz\u00e1lez\u2010Vallinas M., Molina S., Vicente G., et al. Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells. Electrophoresis . 2014;35(11):1719\u20131727.", "ArticleIdList": ["24615943"]}, {"Citation": "Holohan C., van Schaeybroeck S., Longley D. B., Johnston P. G. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer . 2013;13(10):714\u2013726. doi: 10.1038/nrc3599.", "ArticleIdList": ["10.1038/nrc3599", "24060863"]}, {"Citation": "Kars M. D., Iseri O. D., G\u00fcnd\u00fcz U., Ural A. U., Arpaci F., Molnar J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Research . 2006;26(6):4559\u20134568.", "ArticleIdList": ["17201178"]}, {"Citation": "Xu H. B., Li L., Fu J., Mao X. P., Xu L. Z. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by \ud835\udefd-elemene. Pharmacology . 2012;89(5-6):303\u2013312.", "ArticleIdList": ["22573000"]}, {"Citation": "Cridge B. J., Larsen L., Rosengren R. J. Curcumin and its derivatives in breast cancer: current developments and potential for the treatment of drug-resistant cancers. Oncology Discovery . 2013;1:p. 6."}, {"Citation": "Shindikar A., Singh A., Nobre M., Kirolikar S. Curcumin and resveratrol as promising natural remedies with nano-medicine approach for the effective treatment of triple negative breast cancer. Journal of Oncology . 2016;2016:13. doi: 10.1155/2016/9750785.9750785", "ArticleIdList": ["10.1155/2016/9750785", "PMC4875984", "27242900"]}, {"Citation": "Braicu C., Gherman C. D., Irimie A., Berindan-Neagoe I. Epigallocatechin-3-gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. Journal of Nanoscience and Nanotechnology . 2013;13(1):632\u2013637. doi: 10.1166/jnn.2013.6882.", "ArticleIdList": ["10.1166/jnn.2013.6882", "23646788"]}, {"Citation": "Al Dhaheri Y., Attoub S., Ramadan G., et al. Carnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer. PLoS One . 2014;9(10, article e109630)", "ArticleIdList": ["PMC4192122", "25299698"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "13"}, {"Year": "2022", "Month": "7", "Day": "6"}, {"Year": "2022", "Month": "7", "Day": "26"}, {"Year": "2022", "Month": "8", "Day": "26", "Hour": "2", "Minute": "29"}, {"Year": "2022", "Month": "8", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["36017236", "PMC9398845", "10.1155/2022/6044640"]}}], "PubmedBookArticle": []}